Bristol-Myers Squibb (NYSE:BMY) reported very positive first quarter results on Thursday morning, with revenues as well as earnings growing at an attractive pace. Earlier this year we heard chatter about a takeover of BMY by either Gilead (NASDAQ:GILD) or another big pharma -- since Bristol-Myers Squibb hasn't gotten expensive yet and due to the strong results we have seen now, BMY looks increasingly attractive for a takeover.
source: finviz.com
Bristol-Myers Squibb trades at $56, up 4% today, as the market seems to like the first quarter's results. BMY's shares still trade 26% below the 52-week high though, and the market capitalization of $90 billion is in a region that could be affordable for some companies.
